Language: BG BG
nav.cta
← Back to results
Recruiting Phase 1 2024-519010-31-00

A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

Phase 1 – testing safety in a small group of people
Conditions: High-Risk Surgically Resectable Melanoma

Sponsor: Fondazione Melanoma Onlus

trial.available_in: БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 80 participants
Locations 1
Italy (1)
Technical details
Status
Recruiting
Phase
Phase 1
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
15.09.2025
Registry ID
2024-519010-31-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.